Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease-Reference-Cited by-同舟云学术

Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease

Published:2020-12-29 Issue:2 Volume:73 Page:347-354
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Zonozi Reza¹^ORCID,Wallace Zachary S.¹^ORCID,Laliberte Karen¹,Huizenga Noah R.¹,Rosenthal Jillian M.¹,Rhee Eugene P.¹,Cortazar Frank B.²^ORCID,Niles John L.¹

Affiliation:

1. Massachusetts General Hospital Boston

2. Massachusetts General Hospital, Boston, and New York Nephrology Vasculitis and Glomerular Center Albany

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41501

Reference34 articles.

1. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

2. Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

3. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center

4. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis

5. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Severe Neutropenia Following Rituximab Treatment in Patients with Multiple Sclerosis;Journal of Multiple Sclerosis and Neuroimmunology;2024-06-30

2. Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis;Doklady Biochemistry and Biophysics;2024-06-10

3. Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies;Cureus;2024-01-10

4. Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis;Internal Medicine;2024

5. Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial;Annals of the Rheumatic Diseases;2023-12-11